Want to see HK:2142 full AI Analyst Report?
2142 Stock Chart & Stats
HK$12.08
HK$0.18(8.04%)
At close: 4:00 PM EST
HK$12.08
HK$0.18(8.04%)
Day’s Range― - ―
52-Week RangeHK$9.46 - HK$17.07
Previous CloseN/A
Volume9.30M
Average Volume (3M)10.90M
Market Cap
HK$12.05B
Enterprise ValueHK$6.74K
Total Cash (Recent Filing)HK$359.55M
Total Debt (Recent Filing)HK$89.70M
Price to Earnings (P/E)17.5
Beta1.45
Next Earnings
Mar 31, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.10
Shares Outstanding901,098,500
10 Day Avg. Volume11,469,223
30 Day Avg. Volume10,898,342
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.37
Price to Sales (P/S)7.82
P/FCF Ratio17.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$20.00Price Target Upside65.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.11
Revenue Forecast (FY)HK$234.56M
Bulls Say, Bears Say
Bulls Say
Sharp 2025 Revenue And Margin ImprovementThe 2025 combination of exceptional revenue growth and very high margins indicates strong recent commercial and earnings performance. If maintained, this can provide substantial internal funding for research, market expansion, and operating resilience while strengthening the company’s competitive position.
Improving Leverage And Stronger Equity BaseLower leverage and a larger equity base improve financial flexibility and reduce the balance sheet burden associated with debt. This gives HBM more capacity to absorb operating fluctuations and fund strategic priorities without relying as heavily on additional borrowing.
Positive Operating And Free Cash FlowPositive operating and free cash flow show that 2025 earnings were supported by cash generation rather than remaining solely accounting-based. Strong conversion can help fund development, preserve liquidity, and support sustainable growth with less dependence on external capital.
Bears Say
Material Revenue VolatilityThe sharp swing from a year of declining revenue to exceptional growth makes the recent trajectory difficult to establish as durable. Such variability can complicate planning, resource allocation, and investment decisions, while increasing uncertainty around the company’s recurring growth base.
Uneven Historical Cash GenerationAlthough cash generation improved materially in 2025, the earlier pattern of cash burn and negative cash flow shows that liquidity performance can change substantially across periods. Continued volatility could constrain reinvestment, increase funding needs, and reduce confidence in self-financed growth.
Profitability Remains Dependent On Sustained TurnaroundThe strong 2025 balance sheet and profitability improvements follow several years of weak or negative returns, indicating that financial strength is closely linked to maintaining the current earnings recovery. A reversal could weaken returns, equity support, and overall balance sheet quality.
HBM Holdings Ltd. News
2142 FAQ
What was HBM Holdings Ltd.’s price range in the past 12 months?
HBM Holdings Ltd. lowest stock price was HK$9.46 and its highest was HK$17.07 in the past 12 months.
What is HBM Holdings Ltd.’s market cap?
HBM Holdings Ltd.’s market cap is HK$12.05B.
When is HBM Holdings Ltd.’s upcoming earnings report date?
HBM Holdings Ltd.’s upcoming earnings report date is Mar 31, 2027 which is in 181 days.
How were HBM Holdings Ltd.’s earnings last quarter?
HBM Holdings Ltd. released its earnings results on Aug 27, 2026. The company reported HK$0.627 earnings per share for the quarter.
Is HBM Holdings Ltd. overvalued?
According to Wall Street analysts HBM Holdings Ltd.’s price is currently Undervalued.
Does HBM Holdings Ltd. pay dividends?
HBM Holdings Ltd. does not currently pay dividends.
What is HBM Holdings Ltd.’s EPS estimate?
HBM Holdings Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does HBM Holdings Ltd. have?
HBM Holdings Ltd. has 901,098,500 shares outstanding.
What happened to HBM Holdings Ltd.’s price movement after its last earnings report?
HBM Holdings Ltd. reported an EPS of HK$0.627 in its last earnings report. Following the earnings report the stock price went down -1.451%.
Which hedge fund is a major shareholder of HBM Holdings Ltd.?
Currently, no hedge funds are holding shares in HK:2142
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HBM Holdings Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-11.66%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
40.04%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
HBM Holdings Ltd.
HBM Holdings Limited is a clinical-stage biopharmaceutical enterprise focused on identifying and developing unique antibody-based treatments for a variety of immunological conditions and cancers. The company's pipeline includes several promising assets. In immunology, Batoclimab (HBM9161) is a human monoclonal antibody specifically designed to bind and inhibit the neonatal fragment crystallizable receptor, while Tanfanercept (HBM9036) is under development to address moderate to severe dry eye disease. For oncology, HBM Holdings is advancing various therapies, such as HBM7008, a bispecific antibody targeting tumor-associated antigens, and HBM4003, a human anti-CTLA-4 antibody. Additional cancer candidates in their portfolio include HBM9302 for breast and gastric cancers, HBM7020 for multiple myeloma, and a suite of treatments—HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022—geared towards solid tumors. Furthermore, HBM9022 is being developed to treat SARS-COV-2. Operating globally, HBM Holdings has a presence in Mainland China, the United States, Europe, and other international markets. The company also fosters strategic partnerships for antibody-drug conjugate (ADC) projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was founded in 2016 and is based in Shanghai, People's Republic of China.
2142 Stock 12 Month Forecast
Average Price Target
HK$20.00
▲(65.56% Upside)
Technical Analysis
Alphamab Oncology
―
Everest Medicines Ltd.
―
Lepu Biopharma Co. Ltd. Class H
―
CARsgen Therapeutics Holdings Ltd.
―
CStone Pharmaceuticals
―